Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8165313 | 1.00 | CA1 (0.39) | CA1CA2CA4KMT2ACYP19A1 | |
| SCHEMBL16359987 | 1.00 | CA1 (0.39) | CA1CA2CA4KMT2ACYP19A1 | |
| SCHEMBL2690489 | 0.93 | CA1 (0.43) | CA1CA2CA4KMT2ACYP19A1 | |
| Cycloheptanone SCHEMBL15986210 | 0.88 | KMT2A (0.44) | CA1CA2CA4KMT2ACYP19A1 | |
| SCHEMBL5700793 | 0.86 | CA1 (0.37) | CA1CA2CA4KMT2ACYP19A1 | |
| SCHEMBL2691519 | 0.85 | — | — | |
| SCHEMBL1381228 | 0.76 | KDM4E (0.32) | KMT2ALMNAPOLBACHEMEN1 | |
| SCHEMBL3643910 | 0.76 | CA1 (0.39) | CA1CA2CA4KMT2ACYP19A1 | |
| SCHEMBL6783685 | 0.76 | CA1 (0.35) | CA1CA2CA4KMT2ACYP19A1 | |
| SCHEMBL1379019 | 0.74 | POLB (0.30) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711010-A2 | PRO-PERFUME COMPOSITIONS | Firmenich SA (CH) | 2026-03-18 | — | — | EP | claimed |
| US-20260068882-A1 | ARTHROPOD CONTROLLING COMPOSITION | FIRMENICH & CIE (CH) | 2026-03-12 | — | — | US | claimed |
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| CN-113873884-B | Arthropod control composition | 弗门尼舍有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-20240189737-A1 | COMPOSITIONS FOR LOW-TEMPERATURE DISTILLATION OF HIGH-BOILING-POINT MOLECULES | Natural Extraction Systems, LLC | 2024-06-13 | — | — | US | claimed |
| US-11977060-B1 | Methods of detecting predators in algal cultures | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2024-05-07 | — | — | US | claimed |
| WO-2024073147-A1 | COMPOSITIONS FOR LOW-TEMPERATURE DISTILLATION OF HIGH-BOILING-POINT MOLECULES | Natural Extraction Systems, LLC (US) | 2024-04-04 | — | — | WO | claimed |
| WO-2024073146-A2 | COMPOSITIONS FOR LOW-TEMPERATURE DISTILLATION OF HIGH-BOILING-POINT MOLECULES | Natural Extraction Systems, LLC (US) | 2024-04-04 | — | — | WO | claimed |
| EP-3475256-B1 | DEHYDROGENATION REACTION | FIRMENICH & CIE (CH) | 2024-01-24 | — | — | EP | claimed |
| WO-2005051940-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-09 | — | — | WO | claimed |
| WO-2005014569-A1 | 1,2,4,-TRIOXEPANES AS PRECURSORS FOR LACTONES | AKZO NOBEL N.V. (NL) | 2005-02-17 | — | — | WO | claimed |
| US-20050027142-A1 | Vapor phase reduction of ketoisophorone in presence of catalyst | DEGUSSA AG (DE) | 2005-02-03 | — | — | US | claimed |
| US-6111125-A | Preparation of (1R,4S)-4-hydroxy-1,2,2-trimethylcyclopentyl methyl ketone and derivatives and stereoisomers of this compound | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-29 | — | — | US | claimed |
| EP-0671378-B1 | Process for the preparation of (1R,4S)-4-hydroxy-1,2,2-trimethylcyclopentyl-methylketone, its derivatives and stereoisomers | BASF AG (DE) | 1997-01-29 | — | — | EP | claimed |
| EP-0671378-A1 | Process for the preparation of (1R,4S)-4-hydroxy-1,2,2-trimethylcyclopentyl-methylketone, its derivatives and stereoisomers | BASF AKTIENGESELLSCHAFT (DE) | 1995-09-13 | — | — | EP | claimed |
| US-4588849-A | Process for the preparation of an isomeric mixture of 1-(2,6,6-trimethylcyclohexyl)-hexan-3-ol | FIRMENICH SA (CH) | 1986-05-13 | — | — | US | claimed |
| EP-0118817-B1 | PROCESS FOR THE PREPARATION OF AN ISOMERIC COMPOSITION OF 1-(2,6,6-TRIMETHYLCYCLOHEXYL)-HEXAN-3-OL, USE OF THE OBTAINED COMPOSITION AND INTERMEDIATE CARBINOLS | FIRMENICH SA (CH) | 1986-04-02 | — | — | EP | claimed |
| US-4493904-A | COORDINATION, POLYMERIZATION CATALYST CONTAINING TITANIUM TRICHORI | CONOCO INC. (US) | 1985-01-15 | — | — | US | claimed |
| EP-0118817-A1 | Process for the preparation of an isomeric composition of 1-(2,6,6-trimethylcyclohexyl)-hexan-3-ol, use of the obtained composition and intermediate carbinols | FIRMENICH SA (CH) | 1984-09-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260068882-A1 | ARTHROPOD CONTROLLING COMPOSITION | CNOT9, MSL1, MT-CO2 | CA1 1607/4885CA2 1318/4885CA4 1089/4885 |
| US-20050027142-A1 | Vapor phase reduction of ketoisophorone in presence of catalyst | DOHH, TKT, AKR1C2 | CA1 1072/4885CA2 1480/4885CA4 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.